Abstract
We report here a 58-year-old patient with clonal FIP1L1-PDGFRA-positive
hypereosinophilic syndrome (HES), with skin and lung involvement,
treated with Imatinib, in clinical, hematological and molecular
remission. After 77 months of treatment, Imatinib was stopped and at 9
months of discontinuation, the patient remained in complete molecular
remission.